Valuation: Axsome Therapeutics, Inc.

Market Cap 12.07B 10.5B 9.77B 8.97B 16.94B 1,153B 17.2B 115B 45.2B 574B 45.35B 44.35B 1,924B P/E 2026 *
-114x
P/E 2027 * 42.3x
Enterprise Value 11.96B 10.4B 9.68B 8.89B 16.78B 1,142B 17.04B 114B 44.78B 569B 44.93B 43.94B 1,907B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 7.32x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-6.66%
1 week-9.15%
Current month-10.55%
1 month-9.02%
3 months+6.01%
6 months+17.79%
Current year+19.88%
1 week 218.34
Extreme 218.34
245.5
1 month 218.34
Extreme 218.34
252.6
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/5/26 Free

Director

1,721 0.0033%
4/22/26 Fiscal year

Executive/Senior Manager

22,500 0.0440%
Change 5-day change 1-year change 3-year change Capi.($)
-6.65%-9.15%+115.96%+179.01% 12.07B
+1.31%+13.44%+36.43%+0.31% 75.12B
+2.72%-9.39%+17.04%+176.83% 47.63B
-2.75%+48.50%+48.50%+48.50% 49.48B
-3.81%+6.32%-54.61%-53.87% 42.95B
-1.27%+1.65%+60.57%-23.93% 30.72B
-2.46%+1.91%+60.13%+88.20% 24.93B
-3.85%+5.59%+93.13%-51.48% 22.98B
-1.59%-4.78%-11.93%+136.89% 19.56B
-0.42%+2.89%+74.55%+128.45% 17.19B
Average -1.86%+1.83%+43.98%+62.89% 34.26B
Weighted average by Cap. -1.11%+3.03%+33.71%+46.28%

Financials

2026 *2027 *
Net sales 979M 851M 792M 727M 1.37B 93.45B 1.39B 9.34B 3.66B 46.52B 3.68B 3.6B 156B 1.6B 1.39B 1.29B 1.19B 2.24B 152B 2.27B 15.23B 5.98B 75.87B 6B 5.86B 254B
Net income -107M -93.27M -86.82M -79.71M -151M -10.24B -153M -1.02B -402M -5.1B -403M -394M -17.1B 309M 269M 250M 230M 434M 29.51B 440M 2.95B 1.16B 14.69B 1.16B 1.14B 49.26B
Net Debt -111M -96.23M -89.57M -82.23M -155M -10.57B -158M -1.06B -414M -5.26B -416M -407M -17.64B -394M -342M -319M -293M -552M -37.59B -561M -3.76B -1.47B -18.72B -1.48B -1.45B -62.75B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-31 $219.25 -6.56% 435,633
26-07-30 $234.64 +3.17% 714,361
26-07-29 $227.42 -2.89% 523,066
26-07-28 $234.20 -1.75% 404,143
26-07-27 $238.37 -1.09% 773,053
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
234.64USD
Average target price
282.51USD
Spread / Average Target
+20.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock